Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Greg Korpanty"'
Publikováno v:
BMJ Open, Vol 12, Iss 5 (2022)
Externí odkaz:
https://doaj.org/article/693abc0c3066417fb666e10c12b371f9
Autor:
Martin P. Barr, Anne-Marie Baird, Sophia Halliday, Petra Martin, Emma H. Allott, James Phelan, Greg Korpanty, Linda Coate, Cathal O’Brien, Steven G. Gray, Jane S. Y. Sui, Brian Hayes, Sinead Cuffe, Stephen P. Finn
Publikováno v:
Diagnostics, Vol 12, Iss 10, p 2360 (2022)
The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth factor receptor (EGFR) positive disease (n = 21) were stratified int
Externí odkaz:
https://doaj.org/article/57653e20063243da8a3fe1ac5629d75d
Autor:
Carolyn Moloney, Paula Lynch, Ruth Kieran, Orla Holmes, Greg Korpanty, John Stratton, John McCaffrey, Austin Duffy, Paula Calvert, Anees Hassan, Roshni Kalachand
Publikováno v:
Ovarian cancer.
Publikováno v:
Journal of Clinical Oncology. 41:91-91
91 Background: Neoadjuvant treatment (NAT) followed by surgery has become the standard treatment for locally advanced rectal cancer (LARC). This scoping review aims to assess the toxicity and outcomes of the currently available NAT of rectal cancer i
Autor:
Ruba Hamed, Sam Marks, Helen Mcelligott, Roshni Kalachand, Hawa Ibrahim, Said Atyani, Greg Korpanty, Nemer Osman
Publikováno v:
Molecular and Clinical Oncology
Systemic therapy is the mainstay of treatment for de novo metastatic colorectal cancer (mCRC). Heterogeneity between primary tumours and metastases may lead to discordant responses to systemic therapy at these sites. The aim of the present study was
Publikováno v:
BMJ Open. 12:e061397
IntroductionColorectal cancer remains the second leading cause of cancer-related death in 60–79 years old and the third leading cause of death in patients aged 80 and above. Rectal cancer accounts for approximately a third of colorectal cancer diag
Publikováno v:
Annals of Oncology. 32:S161
The impact of the COVID-19 pandemic on oncology clinical trial recruitment in an Irish cancer center
Autor:
Linda Coate, Roshni Andrew Kalachand, Valerie Madigan, Maureen O'Grady, Greg Korpanty, Ronan Andrew McLaughlin, Nemer Osman, Thamir Mahgoub
Publikováno v:
Journal of Clinical Oncology. 39:e18756-e18756
e18756 Background: The COVID-19 pandemic has created unprecedented disruptions to cancer clinical trial research across the world due to a temporary global suspension of patients’ recruitment to cancer clinical trials. Access to clinical trials per
Publikováno v:
Journal of Clinical Oncology. 39:136-136
136 Background: Colorectal cancer (CRC) is the 3rd most common malignancy in Ireland with over 2700 cases annually. Approximately 20% are diagnosed with stage IV disease. The aim of this study is to evaluate the response to chemotherapy at primary an
Autor:
John J. O'Leary, Kirsten Timms, Jennifer Potter, Danielle Gallagher, Yang Li, Mattia Cremona, Mickaël Renaud, Britta K. Stordal, Jie Li, Deborah Williams, Thanh Tran, Gordon B. Mills, Ozlem Aslan, Steven Busschots, Greg Korpanty, Mark S. Carey, Angela M. Farrelly, Bryan T. Hennessy, Julien Thery
Publikováno v:
Molecular Oncology. 7:567-579
Mutations in BRCA1/2 increase the risk of developing breast and ovarian cancer. Germline BRCA1/2 mutations occur in 8.6-13.7% of unselected epithelial ovarian cancers, somatic mutations are also frequent. BRCA1/2 mutated or dysfunctional cells may be